Charles Schwab introduces 24/7 crypto futures trading and expanded features

Charles Schwab announced enhancements to its trading platforms, including the introduction of 24/7 cryptocurrency futures trading on its thinkorswim platform suite. The company, which manages $12.61 trillion in total client assets, made select cryptocurrency futures for Bitcoin, Ether, Solana and Ripple available for trading nearly around the clock.

The brokerage expanded its fractional trading capabilities to include most U.S. stocks and ETFs, lowering the minimum investment requirement to $1. Clients can now invest using dollar amounts rather than share quantities directly through Schwab's trade ticket.

Additional platform updates include expected price range information for marginable securities on Schwab.com and dividend reinvestment settings adjustment through the Schwab Mobile app. The mobile platform also received enhanced fixed income positions display and customizable order status quotes.

The thinkorswim desktop platform will receive specified lots functionality, allowing clients to choose which tax lots are designated for sale. The platform's paperMoney simulation tool will add an Order Gadget with enhanced options pricing information and full options chain visibility.

"A diverse range of clients seek out Schwab for the best-in-class trading experience we offer, from our award-winning platforms to our 24-hour specialized support and education," said James Kostulias, Managing Director and Head of Trading Services at Charles Schwab.

The cryptocurrency futures trading is provided through Charles Schwab Futures and Forex LLC, a registered Futures Commission Merchant. The company processes an average of 10.3 million daily trades, according to April 2026 data provided in the press release.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Loop Industries receives C$2.92 million government funding for recycling tech
• Darling Ingredients receives US patent for blood glucose collagen peptide